β-adrenergic blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor–neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium–glucose cotransporter-2 inhibitors should be initiated when hemodynamically tolerated, consistent with guideline-directed therapy for dilated cardiomyopathy and severe systolic dysfunction [5,42]. This evidence concerns the gene NR3C2 and dilated cardiomyopathy.